PureTech Health plc (NASDAQ:PRTC – Get Rating) saw a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 1,400 shares, a decrease of 17.6% from the March 31st total of 1,700 shares. Based on an average daily volume of 900 shares, the short-interest ratio is presently 1.6 days.
PureTech Health Price Performance
Shares of PRTC stock opened at $25.75 on Friday. PureTech Health has a fifty-two week low of $18.15 and a fifty-two week high of $38.90. The stock's 50-day moving average is $27.63 and its two-hundred day moving average is $29.83.
Get PureTech Health alerts:Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. OLD Mission Capital LLC acquired a new position in PureTech Health in the 4th quarter worth about $207,000. Jane Street Group LLC acquired a new position in PureTech Health in the 4th quarter worth about $269,000. Finally, AWM Investment Company Inc. increased its position in PureTech Health by 1,857.1% in the 4th quarter. AWM Investment Company Inc. now owns 1,370,000 shares of the company's stock worth $6,420,000 after purchasing an additional 1,300,000 shares during the last quarter. 0.25% of the stock is owned by institutional investors and hedge funds.
About PureTech Health
(Get Rating)
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.
Recommended Stories
- Get a free copy of the StockNews.com research report on PureTech Health (PRTC)
- MarketBeat Week in Review – 4/24 – 4/28
- How to Invest in the Top Grocery Stocks for This Year
- Array Technologies Brings Solar Flare To 2023 Earnings Forecast
- Best Bank Stocks to Invest in Ahead of Rising Interest Rates
- How to Invest in Farmland: 7 Simple Ways
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.